What are Strattera and Qelbree, and how are they used for ADHD?
Strattera is the brand name for atomoxetine, a non-stimulant medicine used to treat ADHD in children, adolescents, and adults.
Qelbree is the brand name for viloxazine extended-release, another non-stimulant option used for ADHD.
How do they work differently?
Both are non-stimulants, but they target different neurotransmitter pathways. Strattera (atomoxetine) is a selective norepinephrine reuptake inhibitor (SNRI). Qelbree (viloxazine ER) works through norepinephrine-related mechanisms as well, with additional effects on brain signaling relevant to ADHD symptoms.
Which one tends to be chosen first, and what’s the practical difference for patients?
In real-world prescribing, the choice often comes down to individual factors such as:
- Other medical conditions
- Other medications a person takes (drug interactions)
- How quickly symptoms need to improve
- Side-effect preferences (for example, tolerability of nausea vs sleep-related effects)
- Past response to non-stimulants or stimulants
Because both are non-stimulants, they are commonly chosen when stimulants aren’t suitable, aren’t tolerated, or are not desired.
How long do they take to work?
Both are typically not “instant” like many stimulants. Symptom improvement often takes days to weeks, with the full benefit building over time. The exact timeline can vary by person and dose.
What side effects are people most concerned about?
Patients commonly look for differences in tolerability between non-stimulant ADHD options. Side effects can differ in likelihood and type between atomoxetine and viloxazine ER, so the best fit depends on what a person experiences first after starting and during dose adjustments.
If you tell me the age of the patient and any key concerns (sleep, appetite/weight, anxiety, blood pressure, heart history, liver issues, or current meds), I can narrow down the comparison to the most relevant risk-and-tolerability areas.
Are there safety differences that matter for certain medical histories?
Yes—non-stimulant ADHD medicines can have different cautions depending on the person’s health history (for example, liver-related concerns, heart-rate or blood-pressure issues, mood changes, or medication interactions). The right choice depends on the clinician’s review of the patient’s risks and current prescriptions.
Can they be switched or combined?
Switching between non-stimulants is sometimes done when one medicine isn’t tolerated or doesn’t work well enough. Combination with other ADHD medications is also sometimes considered, but it must be managed by a prescriber due to interaction and side-effect overlap. Never switch or combine without clinician guidance.
Which one is more effective?
Direct “Strattera vs Qelbree” head-to-head effectiveness comparisons are limited, and results vary person to person. Many clinicians approach the decision by matching the medicine to the patient’s side-effect profile and prior response history, then adjusting based on symptom improvement and tolerability.
Cost and insurance: what usually drives the decision?
Even when two options are clinically similar, coverage can be a deciding factor. Formularies, prior authorization requirements, copays, and whether a generic is available can affect what’s realistically accessible. Strattera has a generic route (atomoxetine), while Qelbree’s cost can depend on current availability and coverage.
Key practical next steps
If you’re deciding between the two, the most useful things to compare with your prescriber are:
- Age and dosing schedule
- Your main ADHD symptoms (inattention vs impulsivity vs hyperactivity)
- Sleep and appetite history
- Any liver, blood pressure/heart rhythm, or mood/anxiety history
- Current medications and substance use
- What you’ve tried before and what happened
If you share the patient’s age and a few relevant details (current meds, main side effects you want to avoid, and any heart/liver or mood history), I can give a more targeted Strattera vs Qelbree comparison.